CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
The findings, presented today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight advances researchers are making to develop more effective therapies for patients...
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform that generates...
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership agreement...
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers — ATR inhibitor elimusertib and PARP inhibitor AZD5305 — are safe and clinically beneficial in treating patients with advanced solid tumors. Principal investigator Timothy Yap, M.B.B.S., Ph.D., associate professor of Investigational Cancer Therapeutics, today presented new data from the trials at the American...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created Banner...
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk...
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy...
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...